Oruka Therapeutics, Inc. (ORKA) stock
ORKANasdaqPharmaceutical PreparationsFiscal year ends December 31
$96.32−2.92 (-2.94%)
Close on Nov 17, 2026Market cap $6.38BP/E –Yield –
Oruka Therapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Oruka Therapeutics's R&D Expenses for the twelve months ending Jun 30, 2026 was $129.03M. For fiscal 2025 it was $100.64M, up 9834.8% from the year before. Over ten years it grew 33.4% a year on average. The highest annual figure on record is $100.64M in fiscal 2025.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $100.64M | +9834.8% |
| FY2023 | Dec 31, 2023 | $1.01M | -78.7% |
| FY2022 | Dec 31, 2022 | $4.75M | -65.7% |
| FY2021 | Dec 31, 2021 | $13.83M | +177.1% |
| FY2020 | Dec 31, 2020 | $4.99M | +172.3% |
| FY2019 | Dec 31, 2019 | $1.83M | -56.8% |
| FY2018 | Dec 31, 2018 | $4.24M | -69.9% |
| FY2017 | Dec 31, 2017 | $14.08M | +14.0% |
| FY2016 | Dec 31, 2016 | $12.35M | +74.8% |
| FY2015 | Dec 31, 2015 | $7.06M | +25.6% |
| FY2014 | Dec 31, 2014 | $5.63M | +92.1% |
| FY2013 | Dec 31, 2013 | $2.93M | +168.1% |
| FY2012 | Dec 31, 2012 | $1.09M | -52.8% |
| FY2011 | Dec 31, 2011 | $2.32M | -25.5% |
| FY2010 | Dec 31, 2010 | $3.11M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $43.26M | +79.6% |
| Q1 FY2026 | Mar 31, 2026 | $29.15M | +46.3% |
| Q4 FY2025 | Dec 31, 2025 | $27.64M | +7.6% |
| Q3 FY2025 | Sep 30, 2025 | $28.99M | +55.2% |
| Q2 FY2025 | Jun 30, 2025 | $24.09M | +14498.2% |
| Q1 FY2025 | Mar 31, 2025 | $19.93M | +42293.6% |
| Q3 FY2024 | Sep 30, 2024 | $25.69M | +7878.6% |
| Q2 FY2024 | Jun 30, 2024 | $18.67M | +7251.6% |
| Q1 FY2024 | Mar 31, 2024 | $165.00K | -57.7% |
| Q4 FY2023 | Dec 31, 2023 | $47.00K | -23.0% |
| Q3 FY2023 | Sep 30, 2023 | $322.00K | -68.6% |
| Q2 FY2023 | Jun 30, 2023 | $254.00K | -82.9% |
| Q1 FY2023 | Mar 31, 2023 | $390.00K | -82.1% |
| Q4 FY2022 | Dec 31, 2022 | $61.00K | -98.5% |
| Q3 FY2022 | Sep 30, 2022 | $1.02M | -70.2% |
| Q2 FY2022 | Jun 30, 2022 | $1.49M | -58.5% |
| Q1 FY2022 | Mar 31, 2022 | $2.18M | -24.2% |
| Q4 FY2021 | Dec 31, 2021 | $3.94M | +23.0% |
| Q3 FY2021 | Sep 30, 2021 | $3.44M | +841.9% |
| Q2 FY2021 | Jun 30, 2021 | $3.58M | +831.5% |
| Q1 FY2021 | Mar 31, 2021 | $2.88M | +728.8% |
| Q4 FY2020 | Dec 31, 2020 | $3.20M | +628.2% |
| Q1 FY2020 | Mar 31, 2020 | $365.00K | -44.9% |
| Q4 FY2019 | Dec 31, 2019 | $384.00K | -38.6% |
| Q3 FY2019 | Sep 30, 2019 | $347.00K | -53.1% |
| Q2 FY2019 | Jun 30, 2019 | $440.00K | -61.9% |
| Q1 FY2019 | Mar 31, 2019 | $662.00K | -61.5% |
| Q4 FY2018 | Dec 31, 2018 | $625.00K | -77.9% |
| Q3 FY2018 | Sep 30, 2018 | $740.00K | -78.8% |
| Q2 FY2018 | Jun 30, 2018 | $1.15M | -74.4% |
| Q1 FY2018 | Mar 31, 2018 | $1.72M | -47.0% |
| Q4 FY2017 | Dec 31, 2017 | $2.83M | -9.2% |
| Q3 FY2017 | Sep 30, 2017 | $3.49M | -6.2% |
| Q2 FY2017 | Jun 30, 2017 | $4.51M | +54.8% |
| Q1 FY2017 | Mar 31, 2017 | $3.25M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.12M | – |
| Q3 FY2016 | Sep 30, 2016 | $3.72M | – |
| Q2 FY2016 | Jun 30, 2016 | $2.91M | – |
See a number that looks wrong?